리벤텍 주식회사

R&D
Biopharmaceutical development
research service using Libentech platform
technology Oncolytic virus,
gene therapy, protein based medicine, etc.
바로가기
Biopharmaceutical Consulting
Biopharmaceutical Design
QC/QA development
Documentation GMP consulting
바로가기
CDMO
Biopharmaceutical development process service based on the GLP and GMP
바로가기

Company News

Libentech Co., Ltd. was selected for the 2022 SME technology innovation development project. 2022-05-12
Signed an industry-academic cooperation agreement with Chungnam National University Medical Research Center 2022-04-21
[Patent application] Korean patent application for oncolytic virus for colorectal cancer treatment based on LVP-K virus vector containing cancer necrosis factor-related apoptosis inducing ligand gene and colorectal cancer treatment composition using the s 2022-04-06
[Patent application] USA Patent application for oncolytic virus for brain tumor treatment using LVP-K Platform and composition for treatment of glioblastoma (brain tumor) cells using the same 2021-12-09

Guidelines

Biosafety Guidance for Working with Viral Vectors 2022-08-16
Guidance for Industry process validation 2020-03-11
Guidance for Industry CGMP guideline of Phase I Investigational drug 2020-03-11
Preclinical Assessment of Investigational Cellular and Gene Therapy Products 2020-03-09

Customer contact by online

Please contact any kind of your question submit our site we will receive prompt answer by online